A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Allergan150 enrolled

Overview

This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinza™ used for patients with Open-Angle Glaucoma or Ocular Hypertension.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

No InterventionOTHER

No study drug is administered in this study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants treated with Simbrinza™ for Intra-Ocular Pressure (IOP) lowering in at least one eye * Participants who had at least one-follow-up visit with tolerablity and efficacy data after Simbrinza™ treatment initiation. Exclusion criteria: * Active ocular disease other than glaucoma or ocular hypertension * History of any intraocular surgery or glaucoma laser surgery within 3 months.

Locations (1)

Unnamed facility

Wheaton, Illinois, United States

Outcomes

Primary Outcomes

The time to first glaucoma therapy escalation occurrence or discontinuation of Simbrinza®

Time frame: 2 Years

Secondary Outcomes

The time to first glaucoma therapy escalation occurrence

Time frame: 2 Years

The time(s) to additional glaucoma therapy escalation occurrence(s)

Time frame: 2 Years

Specific AEs and SAEs occurring with a frequency of ≥5%

Time frame: 2 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.